Please login to the form below

Not currently logged in
Email:
Password:

Dyax withdraws its European application for hereditary angioedema treatment Kalbitor

US biotech unable to provide sufficient data to support its hereditary angioedema drug for EU approval

US biotech Dyax has withdrawn its European marketing authorisation application for its hereditary angioedema (HAE) drug Kalbitor (ecallantide).

The decision came after the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated Dyax had not provided sufficient evidence to demonstrate a positive benefit-risk balance for Kalbitor.

Dyax said it would consider resubmitting Kalbitor to the EMA once the results of an ongoing bioequivalence study using a high-strength formulation of the drug become available.

Dyax said it will press on with marketing applications and regulatory approvals in other international territories, including Australia, the Middle East and Latin America.

The biotech has already won for Kalbitor in the US, where the drug is approved to treat acute attacks of (HAE) in patients aged 16 years and over.

15th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics